Rxwire
In the news · 48h FDA 39 Eli Lilly 19 Roche 9 Merck & Co. (MSD) 8 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Novo Nordisk 3
Trials & R&D · first seen yesterday, updated yesterday

Merck's Melt-Up Triggers Profit-Taking Risks - Multi-Year Portfolio Renewal (Rating Downgrade)

1 outlet Merck & Co. (MSD)

Coverage 1 article · 1 outlet

  1. Seeking Alpha Healthcare
    Merck's Melt-Up Triggers Profit-Taking Risks - Multi-Year Portfolio Renewal (Rating Downgrade)